TY - JOUR T1 - Monoclonal antibodies for migraine prevention: hope, hype, and health economy challenge JF - British Journal of General Practice JO - Br J Gen Pract SP - e523 LP - e524 DO - 10.3399/bjgp20X711833 VL - 70 IS - 697 AU - David Kernick Y1 - 2020/08/01 UR - http://bjgp.org/content/70/697/e523.abstract N2 - The annual prevalence of migraine in the UK is 7.6% in males and 18.3% in females.1 Migraine is ranked globally as the second most disabling disease,2 and is the second most frequent cause of short-term absence for non-manual employees with a cost of 2.25 billion GBP per year in the UK.1 Over 30% of people with migraine have ≥4 attacks a month, of whom a quarter will have chronic migraine — arbitrarily defined as headache on ≥15 days of the month, of which eight are migraine.3 Chronic migraine has a high impact and is associated with medication overuse headache and deteriorating psychosocial functioning.3Migraine is a complex biopsychosocial disease, and although lifestyle and psychological interventions complement drug treatment, evidence-based interventions for prevention are limited. All preventative drugs have been discovered by chance, and of the wide array of drugs used in practice only beta-blockers, amitriptyline, and topiramate in addition to botulinum toxin for chronic migraine … ER -